Nausea After Eating With Crohn's: Why It Happens

Nausea after eating with Crohn's disease is usually coming from one of four places: a narrowing somewhere downstream that a meal has to get past, a stomach that is emptying too slowly, Crohn's inflammation in the stomach or duodenum itself, or something on your medication list. Those four have different tests, different treatments and different urgency, and the fastest way to start separating them is not a food list. It is a clock.

Specifically: how many minutes after the first bite does the nausea start, and what does it do next. That number is diagnostic gold and almost nobody records it, partly because almost nobody is asked for it. Crohn's clinics are set up to count stools. Nausea sits off the edge of the standard scorecard, which is exactly why people with prominent nausea so often describe feeling like their symptom is treated as background noise.

This guide is for people who already have a Crohn's diagnosis. It goes through each of the four mechanisms, what the timing pattern tends to look like for each, what a clinician can actually test, the medication audit that resolves a surprising share of cases, and the one pattern that means putting the diary down and picking up the phone.

The short answer: four mechanisms, and timing separates them

Postprandial nausea is a signal that something about the arrival of a meal is a problem. In Crohn's disease the plausible causes sort into four groups, and they are not mutually exclusive. Plenty of people have two at once.

1. Mechanical narrowing. A stricture anywhere from the gastric outlet to the terminal ileum turns a normal meal into a bolus that has to squeeze through a smaller hole. Fibrotic strictures are a common complication of Crohn's, affecting approximately half of all patients according to the expert panel that set out to standardise how they are defined (Rieder 2018).
2. Delayed gastric emptying. The stomach empties too slowly, so food sits. This is measurable and, in IBD at least, appears to move with disease activity (Keller 2015).
3. Upper gut Crohn's. Actual inflammation in the stomach or duodenum, which is far from rare and usually silent, but when it does speak it speaks in nausea, early fullness and epigastric pain (Diaz 2015).
4. Everything on your prescription list. Methotrexate, thiopurines, oral iron, opioids, GLP-1 receptor agonists and cannabis all produce nausea or slow the stomach, and the pattern here follows dosing dates rather than meal times.

There is a fifth category that is easy to miss, and it is the one that answers a question people keep asking in the community: nausea that is not coming from your stomach at all, but from what is happening further down. More on that below, because the data on it is genuinely surprising.

Why the gap between the meal and the nausea is the number that matters

Here is the practical core of this guide. Instead of logging "nauseous after lunch", log two clock times and one number: when you started eating, when the nausea started, and how bad it got on a 0 to 10 scale. The gap in minutes is what carries the information.

The table below maps timing patterns onto mechanisms. It is built from the physiology and from how each condition is defined in the literature cited throughout this article, not from a study that validated the mapping, and no such study exists. Treat it as a way to ask a sharper question, not as a diagnosis.

Two things make this more useful than it looks. First, it turns an unfalsifiable complaint into a testable one. "Nausea starts 40 minutes in, only with large or fatty meals, and I sometimes bring up food I recognise" is a referral for a gastric emptying study. "Nausea builds over two hours with cramping and stops after a rush of bowel noise" is a request for cross-sectional imaging. Those are different appointments.

Second, it protects you from the trap that swallows most food diaries. If you only record the food, you will conclude that a specific food is the villain, when the actual variable is usually volume, fat content and texture. Our guide to keeping a food diary for IBS walks through the arithmetic of why informal trigger-hunting throws up so many false positives, and the same problem applies here with the added twist that the relevant exposure is often mechanical rather than chemical.

Narrowing downstream: what a symptomatic stricture actually feels like

If your nausea comes with cramping that builds after a meal, localises to one place, and eases after a loud spell of bowel noise, the question to put to your team is whether you have a stricture.

This is not a fringe possibility. When an interdisciplinary panel of 15 gastroenterologists and radiologists used formal consensus methodology to standardise how stricturing Crohn's should be defined for trials, they defined a symptomatic stricture by exactly this cluster: abdominal distension, cramping, dietary restrictions, nausea, vomiting, abdominal pain and post-prandial abdominal pain (Rieder 2018). Nausea is not an afterthought in that definition. It is one of the seven listed features.

The same consensus defined the anatomical stricture by three findings together: luminal narrowing, bowel wall thickening and pre-stenotic dilation, with MRI considered the optimal technique to identify one and to assess response.

Worth knowing before you go in: how consistently those criteria are actually applied is poor. A 2025 systematic review of 30 imaging studies covering 1,866 patients with Crohn's found that only four studies (13%) required all three descriptors, most used luminal narrowing or wall thickening alone, and pre-stenotic dilation was treated as optional in 77% of them. Pooled sensitivity and specificity for detecting strictures were 0.88 and 0.86 for ultrasound, 0.82 and 0.80 for MR enterography, and 0.83 and 0.77 for CT enterography, with wide confidence intervals for MRI and CT specificity and substantial heterogeneity (Dal Buono 2025). Eight of the 30 studies were judged at high or unclear risk of bias in at least one domain.

Read that as encouraging rather than discouraging: the tests find strictures reasonably well. But "my scan was normal" carries less certainty than it sounds, because what counted as a stricture varied between the studies that established how well the scans work.

Our guide to foods that cause ileostomy blockage covers the mechanics of what physically fails to pass through a narrow segment, and much of it applies to a Crohn's stricture even without a stoma: bulky, intact, fibrous plant material is the usual culprit, and chewing changes the answer more than people expect. If you have a known stricture, texture is a mechanical question to settle with your team rather than by experiment. Our guide to why junk food feels better with Crohn's covers the related question of why softer processed food often passes more comfortably than a salad.

When the stomach itself is the slow part

Delayed gastric emptying is measurable in Crohn's, and the evidence that it matters is better than its near-total absence from patient-facing Crohn's information would suggest.

In a study of 26 people hospitalised with an acute episode of IBD (13 with Crohn's, 13 with ulcerative colitis) alongside 20 healthy controls, nine patients had a pathologically delayed gastric emptying half-time of more than 150 minutes on a carbon-13 octanoic acid breath test. Across the whole IBD group the half-time was significantly longer than in controls (129 minutes against 96). Sixteen patients were retested after three to four months of treatment: both their clinical activity indices and their emptying times had fallen, and emptying no longer differed from healthy controls (Keller 2015). This was a small study and the two IBD conditions were pooled, so the Crohn's-specific effect is not separable from it. But the direction is clear, and the practical implication matters: if slow emptying tracks activity, then nausea appearing during a rough patch may resolve with treatment of the underlying disease rather than with an antiemetic.

A separate study of 27 people with IBD and 26 healthy volunteers found that those with gastroduodenal symptoms had a more pronounced emptying delay, and that satiety and vomiting specifically correlated with emptying time, while epigastric pain did not and instead correlated inversely with active ghrelin (Sales 2019). The authors' conclusion is the useful bit: different symptoms in the same upper abdomen appear to come from different mechanisms, so "my stomach feels wrong" needs unpacking into which specific sensation.

In children, the signal has been visible since the early 1990s. Of 45 children with Crohn's studied over six years, 15 had delayed emptying of the solid component of a meal, 14 of those 15 had preceding weight loss, and 12 complained of upper gastrointestinal symptoms including nausea, early satiety, postprandial epigastric pain and anorexia. Twelve of the 15 had abnormal gastric or duodenal biopsies, and emptying, nutritional status and disease activity all improved after nutritional rehabilitation. Notably, all 25 children with ulcerative colitis had normal emptying (Gryboski 1992). That is a paediatric cohort from a single centre, so the proportions should not be read across to adults, but the coupling of slow emptying with weight loss and upper gut inflammation is the part worth carrying forward.

Why "gastroparesis" is the wrong word to reach for first

Here is a distinction that trips up a lot of people who have read about gastroparesis and recognised themselves in it. Gastroparesis is defined as delayed gastric emptying in the absence of gastric outlet obstruction (Camilleri 2026). The diagnostic standard is gastric emptying scintigraphy showing more than 10% retention at four hours, in someone with the right symptoms and with mechanical obstruction excluded by endoscopy or imaging such as a CT scan.

For most people investigated for gastroparesis, excluding obstruction is a formality. In Crohn's disease it is the whole question. Crohn's is a disease that produces strictures, including at the gastric outlet and in the duodenum. So the order of investigation is reversed compared with, say, diabetes: the mechanical question comes first, and only if it is answered no does the word gastroparesis become available. If a clinician has used the term with you without imaging, that is a reasonable thing to ask about.

For context on the wider condition: in a large US epidemiological study covering 82.6 million patients, the most common causes of gastroparesis were type 2 diabetes (51.7%), postsurgical effects (15%), medication-induced (11.8%), idiopathic (11.3%), type 1 diabetes (5.7%) and other (4.5%) (Camilleri 2026). Crohn's is not on that list as a named cause, which tells you something about how the two literatures have grown up separately. It also means that gastroparesis advice you find online is written for a different population from yours.

Crohn's in the stomach and duodenum: less rare than you were told

Most people are told Crohn's affects the end of the small bowel and the colon. That is where it usually causes trouble, but it is not the whole distribution, and the upper gut numbers are higher than the received wisdom.

A systematic review of 20 studies of gastroduodenal biopsy findings in adults with established Crohn's covered 2,511 patients with Crohn's, of whom 815 had upper gastrointestinal Crohn's. The most common histopathological finding across the whole Crohn's group was non-specific gastric inflammation in 32%, with focal gastritis in 30.9% and gastric granuloma in 7.9%. Endoscopic findings were far less common than histological ones: gastric erythema in 5.9%, erosions in 3.7%, duodenal ulcers in 5.3%. The authors concluded a prevalence of 34% for Crohn's involving the upper gastrointestinal tract (Diaz 2015).

An arithmetic note, because it matters for how you quote this: 815 out of 2,511 is 32.5%, not 34%. The likely benign explanation is that the headline figure pools prevalence across studies rather than summing raw patient counts, which gives a slightly different answer. We could not reconcile the two figures from the abstract, so the honest way to cite this is "around a third", which both readings support.

Two things follow. First, most upper gut Crohn's is silent. A case report describing a diagnosis reached through dyspepsia noted the involvement is asymptomatic in roughly two thirds of patients, which is why routine upper endoscopy with biopsies changes the recorded disease distribution so much. Second, when upper gut Crohn's does become symptomatic, it is frequently mechanical. In a 40-year audit of 54 patients with gastroduodenal Crohn's, the commonest pathology by a wide margin was stricture (41 of 54 patients), followed by ulceration (4) and duodenocutaneous fistula (2). Thirty-three patients (61%) eventually required surgery, and the indication was obstruction in 30 of them (Yamamoto 1999).

That audit is a surgical series from a tertiary referral centre spanning 1958 to 1997, so it describes the severe end of a spectrum treated in a pre-biologic era. It is not a prediction about anybody's course. A more recent single-institution surgical series found upper gut Crohn's in just 2.96% of 811 patients who underwent intestinal surgery for Crohn's, with duodenal or gastric stricture in 41.7% of those and penetrating fistula in 58.3% (Moon 2020). The gap between "a third have histological involvement" and "3% need upper gut surgery" is the reassurance in this section: involvement is common, consequential involvement is not.

The nausea that is not coming from your stomach at all

One of the most-asked questions in the Crohn's community is why nausea, fatigue and general malaise arrive when you are constipated or about to have a bowel movement. A thread in r/CrohnsDisease asking exactly that drew dozens of replies from people describing the same sequence (r/CrohnsDisease thread). It sounds like a folk belief. The data suggests it is not.

In a tertiary gastroenterology practice, 149 patients presenting with chronic nausea or vomiting were investigated with gastric emptying and colonic transit studies, anorectal manometry and balloon expulsion testing. Among the 138 who had both gastric emptying and colonic transit measured, 106 (76%) had entirely normal gastric emptying and normal colonic transit. Only 11 (8%) had isolated delayed gastric emptying. Meanwhile 77 of the 149 patients (52%) had an evacuation disorder, confirmed objectively in 68 of them. The authors concluded that colonic motility and rectal evacuation should be evaluated in people presenting with chronic nausea and vomiting, since about half have abnormalities that could plausibly contribute (Kolar 2014).

Two caveats have to travel with that finding. It is a single-gastroenterologist tertiary referral series, so it describes a selected group of people whose nausea had already defeated earlier attempts at explanation. And it is a general gastroenterology population, not a Crohn's cohort, so the proportions will not transfer. What does transfer is the mechanism: nausea can be generated by what is happening downstream, and a normal gastric emptying study does not close the case.

Practically, this is why the "worse when constipated, better after a bowel movement" column in the table above is worth filling in. It is a cheap observation and it points at a set of investigations nobody would otherwise order for a complaint of nausea.

Morning nausea, before you have eaten anything

Nausea on waking is one of the most common specific complaints in the Crohn's threads, and it is the one where the honest answer is thinnest. There is no Crohn's-specific study of morning nausea. Anyone who gives you a confident single cause has invented it.

What there is, is a list of plausible candidates, each of which produces a slightly different pattern:

• Reflux. A sour taste, a burning sensation, and nausea that is worse lying flat and better once you are upright. Several people in the r/CrohnsDisease morning nausea thread reported that their morning nausea turned out to be reflux and settled once that was treated, which is lived experience rather than evidence, but it points at a question worth asking (r/CrohnsDisease thread).
• Retained food. If emptying is slow, an evening meal can still be in the stomach at 7am. The giveaway is vomiting or belching up food you recognise from the night before.
• An empty stomach. Some people find eating something plain immediately on waking settles it. That is not a treatment and it does not identify a cause, but it is a diagnostic clue in one direction.
• Anxiety on waking. Anxiety and gut symptoms in IBD run in both directions, which is a documented finding rather than an insinuation. In a two-year prospective study of 405 patients with Crohn's or ulcerative colitis, active disease at baseline was associated with an almost six-fold increase in the risk of a later abnormal anxiety score, and among those with quiescent disease, abnormal baseline anxiety scores predicted later need for steroids or a flare (Gracie 2018).
• Medication taken at night. See the medication audit below.

One more look-alike deserves naming because it is easy to miss and it presents in the upper gut: eosinophilic oesophagitis. A systematic review and meta-analysis found the odds of an EoE diagnosis were significantly higher in people with IBD than in the general population (odds ratio 3.9, 95% CI 2.6 to 5.9), though heterogeneity between studies was extreme at I-squared of 99.5%, which means that pooled number should be held loosely (Yanofsky 2025). A screening study that actually went looking found EoE in 1.9% of patients with IBD, with clinically relevant dysphagia in 8.9% of the whole screened cohort (Bäuerle 2026). So it is uncommon in absolute terms but more common than in the general population, and food sticking or a sense of something not going down is the symptom that should prompt asking about it.

Your medication list is a differential diagnosis

If nausea clusters on particular days rather than after particular meals, the calendar is telling you something the food diary cannot. Work through this list with whoever prescribed the medicines. Do not stop or change anything on your own: several of these drugs are what is keeping your disease quiet, and the fix is usually a timing, formulation or supportive change made by your team rather than a stop.

Methotrexate. Nausea is common enough to have its own prevention literature. A Cochrane review of seven trials and 495 patients with refractory Crohn's disease listed nausea and vomiting among the common adverse events, and found withdrawals due to adverse events significantly more frequent on intramuscular methotrexate than placebo in the one large trial that showed benefit: 17% against 2%. In a small comparison against azathioprine, adverse events occurred in 63% of methotrexate patients against 26% on azathioprine (McDonald 2014). Subtracting the comparator matters here: the methotrexate-specific excess in that small study is 37 percentage points, not 63.

Two smaller studies put numbers on the nausea specifically, both in children. A retrospective chart analysis of 202 genotyped children with IBD (87.6% with Crohn's) recorded methotrexate-induced nausea in 34% of the cohort, and found it associated with reduced-function SLCO1B1 *15 alleles (Mehta 2022). A retrospective case-control study at a Canadian children's hospital found nausea in six of ten children with Crohn's who were not given ondansetron premedication, against one of 50 who were, and also recorded anticipatory nausea in 10% of the cohort (Kempinska 2011). Both are paediatric, retrospective and small, and the ondansetron comparison groups were wildly unequal in size, so read them as "this is a known and often manageable problem" rather than as reliable effect sizes.

Thiopurines (azathioprine, mercaptopurine). Roughly 5% to 20% of patients develop gastrointestinal toxicity on thiopurines, and adverse reactions are among the main causes of discontinuation (Zudeh 2021).

Oral iron. Easy to overlook because it feels like a supplement rather than a drug. A meta-analysis of 43 trials and 6,831 adults found ferrous sulfate significantly increased the odds of gastrointestinal side effects compared with placebo (odds ratio 2.32, 95% CI 1.74 to 3.08) and compared with intravenous iron (odds ratio 3.05). In the IBD subgroup specifically, the effect against intravenous iron held at an odds ratio of 3.14 with no heterogeneity. Meta-regression found no significant relationship with dose, which undercuts the common assumption that a smaller tablet will fix it (Tolkien 2015).

Drugs that slow the stomach. The 2022 AGA clinical practice update, as summarised in the 2026 JAMA review, puts discontinuation of medications that delay gastric emptying first among treatment steps, naming opioids, cannabis, anticholinergics and GLP-1 receptor agonists (Camilleri 2026). If you have started a GLP-1 receptor agonist, or your pain is being managed with opioids, that is a live and specific explanation for new postprandial nausea.

A question that comes up repeatedly and has no answer: several people ask whether nausea in the days before a biologic dose is the drug wearing off. We could find no published study addressing nausea in relation to biologic dosing intervals in Crohn's. That is not a no. It means nobody has measured it, so anybody telling you either way is guessing, and your own dated log is genuinely the best available evidence for your case. Our guide to preparing for a GI appointment covers how to put that kind of pattern in front of a clinician in a form they will read.

The cannabis question, because it is the top answer in every thread

In the biggest r/CrohnsDisease thread on zero appetite and severe nausea, which drew 120 replies, cannabis or THC was the most repeated suggestion among the highest-voted comments (r/CrohnsDisease thread). Several people described it as the only thing that works. Separate posters in that thread and in the morning nausea thread described being uncomfortably dependent on it. This deserves a straight answer rather than either enthusiasm or a lecture.

The randomised evidence does not support cannabis for nausea in IBD. A 2026 systematic review followed Cochrane methods and GRADE to assess THC-containing cannabis in IBD. It found four randomised trials and four controlled non-interventional studies. All four RCTs were at high risk of bias, and the non-interventional studies were at serious or critical risk and excluded from evidence rating. Improvements were reported in one trial for bloating and appetite, both rated low quality. And nausea, measured in one trial of 56 people, "consistently failed to differ meaningfully between intervention and control", as did remission, weight, quality of life on the IBDQ and endoscopic scores (Jugl 2026). The reviewers' conclusion was that the evidence is inconclusive overall and that higher quality research is needed given how widely cannabis is used.

Report that as what it is: a negative result on the specific outcome this article is about, from a small trial, inside a review that rated the whole evidence base low to moderate. It does not prove cannabis does nothing for anyone. It does mean the confident community consensus has no trial behind it.

Heavy long-term use can cause the symptom. Cannabinoid hyperemesis syndrome is now a named category in the Rome classification of gastroduodenal disorders, sitting alongside chronic nausea and vomiting syndrome and cyclic vomiting syndrome (Törnblom 2026). It is characterised by cyclic vomiting in a chronic cannabis user, often with relief from hot showers, and it is frequently resistant to standard antiemetics. A systematic review in adolescents found complete cessation of cannabis is currently the only known effective treatment, and noted that 21% of adolescent cases had a history of anxiety or depression (Zhu 2021).

Does nausea mean a flare? Why the scores will not tell you

Nausea can accompany a flare, and it can be entirely mechanical, and the standard clinical activity scores are structurally incapable of distinguishing them, because neither one contains a nausea item.

The Crohn's Disease Activity Index was built in 1976 by collecting 18 candidate predictor variables at 187 visits and using multiple regression to find the subset that best predicted the attending physician's overall rating, then simplifying it to eight selected variables (Best 1976). The patient-reported items that were subsequently extracted from the CDAI diary card to build the modern PRO2 and PRO3 endpoints are stool frequency, abdominal pain and general well-being (Khanna 2015). The Harvey-Bradshaw Index, published in 1980 as a deliberately crude one-day simplification, adds abdominal mass and a complications count to the same core (Harvey 1980). Our walkthrough of what a Harvey-Bradshaw score actually measures goes through each item and what it misses.

So a score of 3 and daily nausea are not a contradiction. They are what happens when a measurement instrument was designed around the symptoms that predicted a 1970s physician's global impression. This is not a minor blind spot. When 247 people with Crohn's or ulcerative colitis in an Irish treatment centre completed a modified symptom assessment scale, they reported a median of 10 symptoms in the last week, rising to as many as 16 in those with active disease, and the authors concluded that clinicians' focus of assessment needs to be broadened to encompass multiple symptoms (Farrell 2016). Lack of energy, not a bowel symptom, was the most burdensome item in that study.

If you want the full walkthrough of separating a genuine Crohn's flare from the things that impersonate one, our guide on how to tell if you are in a Crohn's flare owns that question, including stomach bugs, C. difficile and the symptom-to-endoscopy correlation problem. Three things from the nausea perspective are worth adding here.

Small intestinal bacterial overgrowth. A meta-analysis of 29 studies covering 3,250 people with IBD and 708 controls put the pooled prevalence of SIBO at 31.0% (95% CI 25.2 to 37.1), higher in Crohn's (32.2%) than ulcerative colitis (27.8%), with an odds ratio of 5.25 against healthy controls. Crucially for this article, stricturing or penetrating disease behaviour was a predictor of SIBO (odds ratio 3.51), as were previous abdominal surgery, lower BMI, bloating and flatulence (Feng 2024). Print the disagreement too: a single-centre retrospective series of 128 patients tested by glucose breath test found only 14.1% positive overall, far below the pooled figure, and the difference between active and quiescent disease did not reach significance (Wanzl 2023). Our comparison of SIBO and IBS symptoms covers why these prevalence figures swing so widely, which mostly comes down to the test.

Bile acid malabsorption after ileal resection. More associated with diarrhoea than nausea, but relevant if you have had surgery. In 91 patients with Crohn's and a prior resection who underwent SeHCAT testing, 88 (97%) had retention values under 10%, indicating malabsorption, with a modest correlation between retention and the length of ileum resected (Skouras 2019). That was a group selected for having been tested, so it is not a prevalence figure for everyone post-resection.

IBS-type symptoms in remission. About a third of people with IBD in remission meet criteria for IBS-type symptoms: 32.5% pooled across 27 studies, 36.6% in Crohn's, and lower when remission was confirmed endoscopically at 23.5% (Fairbrass 2020). Over six years of follow-up, these symptoms affected more than two-thirds of patients at some point, fluctuated in most, and were associated with more outpatient appointments and endoscopies, worse anxiety and depression scores, and lower quality of life, but not with worse disease activity outcomes such as steroid need, hospitalisation or resection (Fairbrass 2022). That last part is genuinely reassuring and it cuts both ways: symptoms that are not inflammation still deserve treatment, and they do not predict a worse disease course.

What actually helps, ranked by how good the evidence is

This section deliberately gives no doses, no drug recommendations and no meal plans. What follows is what the literature supports, what population it was tested in, and what to take to your team.

Meal texture and particle size: the best-evidenced dietary lever, in the wrong population. The only randomised trial of a diet aimed at the key symptoms of slow gastric emptying tested a small particle size diet against the recommended diabetes diet in 56 people with insulin-treated diabetes and gastroparesis, over 20 weeks with dietitian support at seven visits. The intervention produced significantly greater reductions in nausea and vomiting, postprandial fullness, bloating and regurgitation or heartburn, though not in abdominal pain. Anxiety also fell in the intervention group (Olausson 2014). That population is people with diabetic gastroparesis, not Crohn's, so the result does not transfer automatically. It does establish that particle size is a variable worth discussing with a dietitian, and it is consistent with the mechanical logic of a stricture. The what to eat during a Crohn's flare guide goes through texture in detail, including why blending changes particle size rather than removing fibre.

Smaller, more frequent meals and lower fat at the difficult meal. No Crohn's trial has tested this. The rationale is direct from the timing data above: if the problem is volume the stomach cannot accommodate or a bolus that has to pass a narrowing, then reducing the volume per sitting addresses the actual variable. It is also the single most commonly reported workaround in the community threads. Treat it as sensible physiology plus widespread lived experience, not as evidence.

Ginger: modest, real, and measured in pregnancy. Ginger is the most recommended non-drug remedy in the Crohn's threads after cannabis. The cleanest summary of its effect comes from pregnancy: in the first trimester, ginger might improve nausea and vomiting by about 4 points on a 40-point scale, or stop vomiting for one in three women at six days (Lindblad 2016). A triple-blind trial of 77 pregnant women found ginger and vitamin B6 both beat placebo, with no significant difference between them, and placebo itself significantly improved several items (Sharifzadeh 2018). No trial has tested ginger for nausea in Crohn's disease. Four points on a 40-point scale is a small effect honestly reported, and that is a reasonable expectation to carry into trying it.

Antiemetics: a clinician's decision, with a real trade-off. Two things are worth knowing before that conversation. In the US, metoclopramide remains the only medication approved for gastroparesis, which tells you how thin the licensed options are (Camilleri 2026). And the 5-HT3 antagonist ondansetron, widely used as an antiemetic, measurably slows the gut: in a randomised crossover trial of 120 patients with IBS with diarrhoea, it improved stool consistency, urgency and frequency compared with placebo (Garsed 2014), and in the follow-up analysis the biggest responders showed a 15.6-hour increase in whole gut transit time (Gunn 2019). That is a benefit if you also have diarrhoea and a problem if your nausea is tied to constipation, which is the loop several people describe in the threads. Both populations were people with IBS with diarrhoea, not Crohn's. Bring the constipation half of your diary to the appointment, because it changes which antiemetic makes sense.

Treating the disease, when the disease is the cause. The Keller finding is the most encouraging thing in this article: emptying times normalised alongside activity indices after three to four months of treatment (Keller 2015). If your nausea arrived with a rough patch, the answer may be upstream of any nausea-specific intervention.

A worked example: three weeks of a nausea log

Two people, the same complaint, different answers. Both examples are constructed to show how the record does the work, not drawn from real patients.

Person A. Crohn's of the terminal ileum, diagnosed nine years ago, one previous resection, currently on a biologic, Harvey-Bradshaw score hovering at 3 to 4. She logs 21 days.

The gap between meal start and nausea onset clusters tightly at 90 to 150 minutes. Severity peaks at 6 or 7. On 11 of the 14 occasions she rated it above 4, the nausea was preceded by cramping that localised to the right lower abdomen, and on nine of those it eased noticeably after a loud spell of bowel noise and a bowel movement. Two of the worst days followed a large salad and a bowl of popcorn. Her stools are formed. She has lost 3 kg without trying.

What that record buys her: a specific question. "My nausea starts 90 to 150 minutes after eating, follows cramping in one place, eases after a bowel movement, and is worst after high-residue meals. Could this be a stricture, and should I have an MRI?" That maps directly onto the consensus definition of a symptomatic stricture (Rieder 2018), and the unintentional weight loss makes it more urgent rather than less.

Person B. Crohn's of the colon, diagnosed 18 months ago, started methotrexate 11 weeks ago, also taking ferrous sulfate for iron deficiency.

His log looks nothing like hers. The nausea has no consistent relationship to meal timing at all. What it does have is a weekly rhythm: it is worst on the day of and the day after his injection, at 7 or 8 out of 10, and drops to 1 or 2 by day four. Separately, he notes nausea about 45 minutes after his morning iron tablet on 16 of 21 days.

What that record buys him: two conversations rather than one, both with the person who prescribed. One is about methotrexate-associated nausea, where a preventive approach exists and has been studied, albeit mostly in children (Kempinska 2011). The other is about oral iron, where the evidence that ferrous sulfate causes gastrointestinal side effects is strong and dose-independent, and where alternative routes exist (Tolkien 2015). Neither is a decision to make alone, and neither would have surfaced from a food diary.

The difference between the two logs is not effort. It is that both recorded a time gap and a date, and let the pattern declare itself. If you would rather not maintain three spreadsheets, Clairop is built for this kind of timestamped logging and turns it into a dated one-page summary for an appointment, with the source of each number shown. It does not interpret your disease and it is not a substitute for your IBD team's assessment.

The quiet cost of eating less to feel less sick

This has to be said because it is the most common unspoken strategy for postprandial nausea, and it has a measurable price.

In a cross-sectional study of 161 adults with IBD recruited from an outpatient clinic, 28 (17%) screened positive for avoidant/restrictive food intake disorder on a validated nine-item screen. Ninety-two per cent reported avoiding one or more foods when symptomatic, and 74% continued to avoid foods in the absence of symptoms. Active symptoms were associated with a positive ARFID screen (odds ratio 5.35) as was inflammation (odds ratio 3.31), and those who screened positive were far more likely to be at risk of malnutrition: 60.7% against 15.8% (Yelencich 2022).

Nausea is a particularly efficient driver of that pattern, because unlike pain it removes the desire to eat rather than just the pleasure. The Gryboski paediatric study is a reminder of where that can end: 14 of the 15 children with delayed gastric emptying had preceding weight loss, and emptying, nutritional status and disease activity all improved together after nutritional rehabilitation (Gryboski 1992).

So if nausea has been shrinking your diet for weeks, ask for a dietitian referral alongside the diagnostic work. Getting more calories in is not a consolation prize for failing to fix the nausea; in that study it was part of what fixed it. The fatigue in Crohn's remission guide covers the overlapping nutritional checks worth asking for, since low iron, low B12 and low energy travel together with a shrinking diet.

Myths about Crohn's nausea worth retiring

"Cannabis is the thing that actually works for Crohn's nausea." The randomised evidence says otherwise. Nausea was measured in one trial of 56 people within a 2026 systematic review and did not differ meaningfully between cannabis and control, and all four included trials were at high risk of bias (Jugl 2026). Bloating and appetite showed improvement in one trial at low evidence quality. Heavy use can also cause cyclic vomiting in its own right (Törnblom 2026).

"A normal Harvey-Bradshaw score means the nausea is not my Crohn's." The score has no nausea item. Neither does the patient-reported core of the CDAI, which is stool frequency, abdominal pain and general well-being (Khanna 2015). A quiet score and severe nausea are compatible, and you should say so out loud in clinic.

"Crohn's doesn't affect the stomach." Around a third of patients have upper gastrointestinal involvement on biopsy, mostly without symptoms (Diaz 2015). Where it does become symptomatic, stricture is the commonest pathology in surgical series (Yamamoto 1999).

"If my stomach empties normally, the nausea is in my head." In a tertiary series of 138 patients with chronic nausea or vomiting, 76% had both normal gastric emptying and normal colonic transit, and about half had a rectal evacuation disorder, which the authors argued could contribute to the nausea (Kolar 2014). A normal emptying study rules out one thing, not everything.

"Gastroparesis explains it." Possibly, but not until obstruction has been excluded, because gastroparesis is defined by delayed emptying in the absence of gastric outlet obstruction (Camilleri 2026). In a disease that produces strictures, that exclusion is the substance of the diagnosis rather than a formality.

"IBS-type symptoms in remission mean my Crohn's is secretly active." Over six years of follow-up, IBS-type symptoms in IBD were associated with more appointments, more endoscopies and worse psychological scores, but not with steroid need, escalation, hospitalisation or resection (Fairbrass 2022). They are real and worth treating. They did not predict a worse disease course.

"Anxiety causing it means it is not physical." Brain-gut interactions in IBD run in both directions, prospectively and measurably: disease activity predicted later abnormal anxiety scores, and abnormal anxiety scores in quiescent disease predicted later flare or steroid need (Gracie 2018). An anxiety contribution is an additional treatable factor, not a dismissal.

"A stricture will show up on any scan." The imaging works reasonably well, but the definitions used in the underlying studies varied enormously, with only 13% requiring all three standard descriptors (Dal Buono 2025). If your symptom pattern strongly suggests a narrowing and one scan was read as normal, that is grounds for a conversation, not a closed file.

When to see a doctor promptly

Some of what follows needs same-day assessment, not a diary entry.

Seek urgent medical help the same day if you have: persistent vomiting you cannot stop, vomiting of food eaten many hours or a day earlier, a distended abdomen with no passage of wind or stool, severe or rapidly worsening abdominal pain, an inability to keep fluids down, signs of dehydration such as very little urine or feeling faint on standing, or a fever with abdominal pain. Those are the features of a bowel obstruction and of other acute complications, and no dietary change treats one.

See a doctor promptly, meaning days not months, for: new or increasing blood in your stool, unexplained weight loss, symptoms that wake you at night, new anaemia or breathlessness and marked fatigue, a new lump or swelling in your abdomen, a new opening or discharge near the anus, or nausea that is new and has persisted for more than a couple of weeks. Any symptom that is new, worsening or has not been assessed belongs with your team rather than in a search engine.

Bring to your next routine appointment: the timing log, the medication calendar, and one specific question. Something like "my nausea starts 40 minutes after eating and only with larger meals, and I have never had a gastric emptying study or an upper endoscopy" is more likely to produce an investigation than "I feel sick a lot".

The honest bottom line

Nausea after eating is one of the most disabling and least measured symptoms in Crohn's disease. It has real, findable causes: a narrowing that a meal has to pass, a stomach emptying too slowly, actual inflammation in the stomach or duodenum, a medication you are taking to stay well, and sometimes a problem further downstream that no one thought to investigate because the complaint was about nausea.

What you can contribute that nobody else can is the timing. The gap between the first bite and the first wave, whether it eases after a bowel movement, and whether it tracks the calendar rather than your meals. Those three observations narrow four possibilities down to one or two, and they turn a vague complaint into a specific request.

What the evidence cannot yet give you is a reliable treatment aimed at the nausea itself. The dietary trial evidence comes from diabetic gastroparesis, the ginger evidence comes from pregnancy, the ondansetron evidence comes from IBS with diarrhoea, and the most popular community remedy failed the one trial that measured it. That is a thin bench. It is also an argument for spending your effort on identifying the mechanism, because the treatments that do work in Crohn's work by fixing the cause: dilating or resecting a stricture, treating active inflammation, changing an iron formulation, adding a preventive strategy around a methotrexate dose.

And if nausea has quietly been shrinking what you eat, treat that as its own problem worth naming in clinic. Eating less is the most available response to feeling sick after meals, and it is the one with a cost that builds while you are distracted by the symptom.